Home > Media Relations > Mercy News Archive

Media Relations: Mercy News Archive

Dr. Sanjay Jagannath joins the Institute for Digestive Health and Liver Disease at Mercy

Sanjay Jagannath, M.D., FASGE, AGAF, Joins Mercy's Institute For Digestive Health And Liver Disease

Board certified gastroenterologist Sanjay Jagannath, M.D., FASGE, AGAF, has joined the medical staff of The Institute for Digestive Health and Liver Disease at Mercy Medical Center, located on the 7th floor of Mercy’s Professional Office Building.

He received his medical degree from the University of Maryland School of Medicine in 1995 and completed his residency in Internal Medicine in 1998 at the University of Colorado Health Sciences Center in Denver, CO. Dr. Jagannath completed his Gastronenterology fellowship at The Johns Hopkins Hospital, including two years of Therapeutic Endoscopy, and a fellowship in Endoscopic Ultrasound Fellowship, in 2002.

Dr. Jagannath previously served as Assistant Professor of Medicine, Director of Endoscopic Ultrasound; Director of the Pancreatitis Center and Program Director for the Advanced Therapeutic Endoscopy Fellowship at Johns Hopkins Hospital.

He has numerous research publications, abstracts, clinical chapters, and professional awards to his credit.

A Fellow of the American Gastroenterology Association, Dr. Jagannath is a member of the American College of Gastroenterology, the American Society of Gastrointestinal Endoscopy and the American Pancreatic Association.

The Institute for Digestive Health and Liver Disease at Mercy addresses inflammatory bowel disease, hepatology, gastroenterology, endoscopy, colon-rectal disorders, and provide Remicade infusion services.

Dr. Jagannath joins renowned physicians Drs. Paul Thuluvath, Mary Harris, and Sergey Kantsevoy, as well as gastroenterologists, Drs. David Posner, Michael Cox, Scott Huber and Patrick Hyatt, and colon-rectal surgeon, Dr. Debra Vachon. Gastroenterologists Drs. Richard Desi and Laura Pichney are also members of the Institute, bringing expertise in community colorectal screening.

At the Institute, patients have access to endoscopic procedures such as interventional endoscopy, endoscopic ultrasound and capsule endoscopy for the diagnosis of digestive and related disorders. The Institute provides expert treatment for bilary tract disease including bile duct cancer; gallstone disease, inflammatory conditions of the colon, Crohn’s Disease, ulcerative colitis, inflammatory bowel and irritable bowel disease, colorectal cancer, esophageal disorders, reflux, swallowing disorders, heartburn, liver disease including hepatitis, and as well as disorders of the pancreas, stomach and duodenum.

The Institute also takes part in clinical trials for Hepatitis B, C, and liver cancer, as well as genetic counseling and preventive medical services, in coordination with Mercy Prevention and Research center under nationally renowned cancer researcher and epidemiologist Dr. Kathy J. Helzlsouer.

Other features to the Institute include a women’s center for diarrheal management, treating inflammatory bowel disease in pregnancy, minimally invasive endoscopic surgery, a comprehensive liver center, including liver transplantation services, and a Remicade infusion center. Remicade (Infliximba) is a drug used to treat autoimmune disorders and has been approved by the USFDA for the treatment of Crohn’s Disease and ulcerative colitis. Remicade is delivered by intravenous infusion or IV, typically at 6-8 week intervals.